Ian del Conde Pozzi, MD
Cardiovascular Disease · Miami, FLNPI 1649309139
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $180,229 of the $243,124 with a category attached, or 74.1%. Johnson & Johnson accounts for 67.7% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $66,917 and has fallen 97.9% since, to $1,397 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 377 payments — averaging $644.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$165K
- Abbott$30K
- Pfizer$19K
- E.r. Squibb & Sons, L.L.C.$11K
- Boston Scientific$9K
- Lantheus Medical Imaging, Inc.$5K
- plus $4K from 21 others
Across 10 payments — averaging $3151.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$32K
What the payments were for
- Consulting fees$32,76013%
- Speaking & faculty fees$180,22974%
- Travel & lodging$17,8357%
- Food & beverage$12,3005%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 180 | $164,614 |
| Abbott | 19 | $30,386 |
| Pfizer | 44 | $18,521 |
| E.r. Squibb & Sons, L.L.C. | 31 | $11,274 |
| Boston Scientific | 19 | $8,905 |
| Lantheus Medical Imaging, Inc. | 11 | $5,439 |
| Medtronic(2 entities) | 14 | $1,858 |
| Atricure, Inc. | 2 | $351 |
| Philips North America LLC | 2 | $272 |
| Impulse Dynamics (USA) Inc. | 4 | $215 |
| Novartis | 11 | $180 |
| Novo Nordisk | 10 | $171 |
| Cleerly, Inc. | 1 | $171 |
| Edwards Lifesciences | 1 | $153 |
| Amgen | 2 | $118 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $105 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $74 |
| Abiomed | 3 | $72 |
| Boehringer Ingelheim | 3 | $62 |
| AstraZeneca | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $37 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Kestra Medical Technology Services, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Lilly USA, LLC | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$162,416
- ELIQUIS$28,614
- Omnilink Elite vascular stent system$14,525
- JETI$9,274
- Watchman$5,415
- Definity$5,196
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$4,500
- WATCHMAN Access System$2,429
- SUPERA$1,487
- WATCHMAN FLX$905
- Amplia MRI$478
- OPTIMIZER$356
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$351
- SYMPLICITY G3$310
- COBALT DR MRI SURESCAN$286
- Micra$174
- Cleerly Ischemia$171
- Cleerly Labs$171
- NAVITOR$170
- Azure$168
How this compares
$243,124 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 446 | $491,578 |
| XareltoRivaroxaban | 209 | $231,144 |
| EntrestoSacubitril/Valsartan | 99 | $109,788 |
| JardianceEmpagliflozin | 74 | $88,399 |
| FarxigaDapagliflozin Propanediol | 67 | $58,904 |
| Repatha SureclickEvolocumab | 26 | $28,829 |
| Praluent PenAlirocumab | 17 | $15,798 |
| BrilintaTicagrelor | 14 | $12,272 |
| Rosuvastatin Calcium | 368 | $4,381 |
| Metoprolol Succinate | 290 | $3,479 |
| Ezetimibe | 102 | $2,615 |
| Atorvastatin Calcium | 251 | $2,547 |
| Bumetanide | 123 | $2,402 |
| Losartan Potassium | 233 | $1,972 |
| Ranolazine ErRanolazine | 12 | $1,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $18,521 | $491,578446 claims |
| Johnson & JohnsonXarelto | $164,614 | $231,144209 claims |
| NovartisEntresto | $180 | $109,78899 claims |
| Boehringer IngelheimJardiance | $62 | $88,39974 claims |
| AstraZenecaFarxiga, Brilinta | $37 | $71,17681 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Miami
- Theodore FeldmanMiami$637K
- Elliott EliasMiami$497K
- Jonathan FialkowMiami$153K
- Bernard AshbyMiami$115K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.